Approximately 50% of patients with EGFR mutant lung cancers who develop acquired resistance to EGFR TKIs have a second-site mutation T790M in the threonine gatekeeper residue that coexists with a primary EGFR activating mutation [38, 39]. Here, EGFR is linked to lung carcinoma.